Company intelligence / Profile preview
Alaya.bio
Cambridge, Massachusetts, USalaya.bio ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Preclinical
01
Overview
Developing in situ CAR-T therapies using targeted polymeric nanoparticles to simplify manufacturing and administration. No clinical results reported yet.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyPolymeric nanoparticlesGene delivery systems
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Nona Biosciences (antibody discovery and conjugation)Columbia University/Michel Sadelain lab (CAR-T research)Memorial Sloan Kettering Cancer Center
Beyond the preview
Go deeper on Alaya.bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alaya.bio.